AlloVir (ALVR) shareholders have approved the company's proposed merger with Kalaris Therapeutics at a special meeting held Wednesday, the companies said the same day.
The merger is expected to close "as soon as practicable" and the combined company will be renamed as Kalaris Therapeutics, with "KLRS" as its updated trading symbol on Nasdaq.